@inbook{e74e2856d24d4a0ea34cf5d40b57175f,
title = "Assays for functionally defined normal and malignant mammary stem cells",
abstract = "The discovery of rare, heterogeneous self-renewing stem cells with shared developmental and molecular features within epithelial components of mammary gland and breast cancers has provided a conceptual framework to understand cellular composition of these tissues and mechanisms that control their number. These normal mammary epithelial stem cells (MaSCs) and breast cancer stem cells (BCSCs) were identified and analyzed using transplant assays (namely mammary repopulating unit (MRU) assay, mammary tumor-initiating cell (TIC) assay), which reveal their latent ability to regenerate respective normal and malignant epithelial tissues with self-renewing units displaying hierarchical cellular differentiation over multiple generations in recipient mice. “Next-generation” methods using “barcoded” normal and malignant mammary cells, with the help of next-generation sequencing (NGS) technology, have revealed hidden complexity and heterogeneous growth potential of MaSCs and BCSCs. Several single markers or combinations of markers have been reported to prospectively enrich MaSCs and BCSCs. Such markers and the extent to which they enrich for MaSCs and BCSCs activity require a critical appraisal. Also, knowledge of the functional assays and their limitations and harmonious reporting of results is a prerequisite to improve our understanding of MaSCs and BCSCs. This chapter describes evolution of the concept of MaSCs and BCSCs, and specific methodologies to investigate them.",
keywords = "Breast, Breast cancer stem cells, Lentiviral DNA barcoding, Limiting dilution analysis, Mammary gland, Mammary repopulating unit (MRU) assay, Mammary stem cells, Tumor initiating cell assay",
author = "Aalam, {Syed Mohammed Musheer} and Beer, {Philip Anthony} and Nagarajan Kannan",
note = "Funding Information: The authors were supported in part by grants to N.K. from Fraternal Order of Eagles Foundation and Mayo Clinic Breast Cancer SPORE (CA116201-12CEP). We thank Dr. John Stingl for critical comments and Dr. Sneha Balani for proof-reading of the manuscript. Funding Information: The authors were supported in part by grants to N.K. from Fraternal Order of Eagles Foundation and Mayo Clinic Breast Cancer SPORE (CA116201-12CEP). We thank Dr. John Stingl for critical comments and Dr. Sneha Balani for proof-reading of the manuscript. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = jan,
day = "1",
doi = "10.1016/bs.acr.2018.12.004",
language = "English (US)",
isbn = "9780128149942",
series = "Advances in Cancer Research",
publisher = "Academic Press Inc",
pages = "129--174",
editor = "Civin, {Curt I.} and Kingsbury, {Tami J.} and MinJung Kim and Fisher, {Paul B.}",
booktitle = "Cancer Stem Cells",
}